Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235546 | 0.86 | L3MBTL1 (0.39) | L3MBTL1EBPSIGMAR1CYP3A4ABCB1 | |
| SCHEMBL7302669 | 0.80 | HPGD (0.42) | L3MBTL1EBPSIGMAR1TSHRGAA | |
| SCHEMBL5754086 | 0.79 | CTSC (0.34) | L3MBTL1EBPSIGMAR1KMT2AMAPT | |
| SCHEMBL7310949 | 0.78 | L3MBTL1 (0.37) | L3MBTL1EBPSIGMAR1CYP3A4ABCB1 | |
| SCHEMBL14432577 | 0.78 | RAB9A (0.43) | L3MBTL1HTR1ADRD2KCNA3OPRM1 | |
| SCHEMBL14432518 | 0.78 | CTSC (0.36) | L3MBTL1EBPSIGMAR1CYP2C19TSHR | |
| SCHEMBL5226414 | 0.78 | CTSC (0.36) | L3MBTL1EBPSIGMAR1CYP2C19TSHR | |
| SCHEMBL5754628 | 0.77 | L3MBTL1 (0.34) | L3MBTL1EBPSIGMAR1CYP3A4 | |
| SCHEMBL5232512 | 0.77 | CCR1 (0.39) | L3MBTL1EBPSIGMAR1MEN1CHRM2 | |
| SCHEMBL5229329 | 0.77 | DPP4 (0.34) | L3MBTL1EBPSIGMAR1CYP2C19ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1254895-B1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | L3MBTL1 4729/4885EBP 560/4885SIGMAR1 143/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | L3MBTL1 4819/4885EBP 964/4885SIGMAR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.